isabelobrien, Author at European Medical Journal - Page 26 of 65

Illustration of vaccine factory.

WuXi Biologics offloads Irish vaccine plant to Merck for $500m

WuXi Biologics sells its vaccine production facility in Ireland to Merck & Co for $500m in the wake of changing regulation in the US.

Gold crown on blue background

Could Eli Lilly take the crown in the obesity market?

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Researchers

Gene therapy from Novartis shows promise for children with SMA

Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal muscular atrophy

Spoonful of technology: Nov-Dec 2024

Discover the latest examples of how pharma and its partners are working together to develop technology to solve key industry challenges.

The word spotlight on a blue background

Spotlight: December 2024

Catch up on all the latest pharmaceutical industry news from the past month, from breakthroughs in gene therapy to promising drug approvals and more.

Pharma review of the year 2024

Look back at the key moments from the past year in pharma with three of our former guests, as they highlight key trends, challenges and more.

stamp of approval

Eli Lilly’s tirzepatide wins FDA nod for sleep apnea

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep disorder.

Tessera's sickle cell gene therapy wins Gates Foundation backing

Tessera Therapeutics has announced a partnership with the Bill & Melinda Gates Foundation, securing funding of up to $50m.

Orange lungs on yellow background

Respiratory infections cost UK businesses £44bn annually

A new report by the Office of Health Economics (OHE), commissioned by Pfizer, reveals that respiratory infections can be bad for business.

Hook, line and sinker: Catching the attention of HCPs

Attention is the new currency in pharma marketing. With HCPs overwhelmed by information, delivering engaging content is crucial to standing out.